| Name | Valganciclovir hydrochloride |
| Description | Valganciclovir hydrochloride (Valganciclovir HCl) is a hydrochloride salt form of valganciclovir, a prodrug form of ganciclovir, a nucleoside analog of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is incorporated into DNA, resulting in inhibition of viral DNA polymerase, and viral replication. |
| In vitro | Valganciclovir is efficiently absorbed through the gastrointestinal tract, with its bioavailability approximately 60% when taken orally after meals. Upon administration, both intestinal and hepatic esterases concurrently hydrolyze the two enantiomers of ganciclovir, inhibiting the replication of human cytomegalovirus. |
| In vivo | In cells infected with Cytomegalovirus (CMV), Valganciclovir is initially phosphorylated by viral protein kinase to its monophosphate form, then further phosphorylated by cellular kinases to produce its triphosphate form. This triphosphate is slowly metabolized within the cell. The phosphorylation process is dependent on viral kinase and preferentially occurs in virus-infected cells. Ganciclovir's antiviral activity is due to the triphosphate form of ganciclovir, which inhibits viral DNA synthesis. The ganciclovir triphosphate gets incorporated into the DNA, replacing many adenine bases, and hindering DNA synthesis as diester bonds take longer to form, thus diminishing the chain's stability. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 127.94 mM, Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.12 mM), Sonication is recommended.
DMSO : 45 mg/mL (115.14 mM), Sonication is recommended.
|
| Keywords | Valganciclovir hydrochloride | Valganciclovir | Inhibitor | inhibit | Cytomegalovirus | CMV | antiviral |
| Inhibitors Related | Rifampicin | Esculin | Phenytoin sodium | Levofloxacin hydrochloride | Hexane-2,5-dione | L-Lysine | L-Lysine hydrochloride | Sodium formate | Ofloxacin | Vidarabine | Thymidine | Danthron |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Drug-induced Liver Injury (DILI) Compound Library | ReFRAME Related Library | Anti-Viral Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | FDA-Approved Drug Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Nucleotide Compound Library |
United States
